SHR-1701

Names

[ CAS No. ]:
2891860-17-4

[ Name ]:
SHR-1701

Biological Activity

[Description]:

SHR-1701 (Retlirafusp alfa) is a bifunctional fusion protein targeting PD-L1 and TGF-β for cancer research[1].

[Related Catalog]:

Research Areas >> Cancer
Signaling Pathways >> Immunology/Inflammation >> PD-1/PD-L1

[In Vitro]

SHR-1701 (10 μg/mL)可以抑制 TGF-β 信号通路，激活 PI3K/Akt/Erk 信号通路，挽救淋巴细胞恢复受损的肺癌患者外周血CD8+ T 细胞的抗肿瘤功能[1]。

[References]

[1]. Bo Cheng, et al. Anti-PD-L1/TGF-βR fusion protein (SHR-1701) overcomes disrupted lymphocyte recovery-induced resistance to PD-1/PD-L1 inhibitors in lung cancer. Cancer Commun (Lond). 2022 Jan;42(1):17-36.  

Chemical & Physical Properties

No Any Chemical & Physical Properties

Related Compounds

The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.